B+
Bull case
30%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
XERS
Xeris BiopharmaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
+0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
News tone is constructive after the Q2 release, led by revenue growth, Recorlev momentum, tighter guidance, and KEVEYIS patent progress. Verified post-release price reaction, analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable; missing data is not treated as positive evidence. The low-coverage setup supports cautious monitoring rather than a high-conviction thesis.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventFY2026 revenue delivery and Recorlev executionHigh impact
Q2 total revenue reached $92.1 million, net product revenue grew 34% year over year, Recorlev revenue grew 81%, and management tightened FY2026 total revenue guidance to $385–$390 million [#SEC-8K-2026-08-06].
2027-09-09catalystKEVEYIS intellectual-property durabilityHigh impact
Xeris reported a USPTO Notice of Allowance for a new KEVEYIS patent expected to extend protection through at least 2039; issuance timing was not disclosed [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology